XAGE-1C Inhibitors
The chemical class of XAGE-1C inhibitors comprises diverse compounds that target various cellular pathways and processes implicated in the regulation of XAGE-1C expression and function. These inhibitors act through both direct and indirect mechanisms to modulate the activity of XAGE-1C, a cancer-testis antigen associated with tumorigenesis and cancer progression. One prominent group of inhibitors includes Nutlin-3, which disrupts the interaction between XAGE-1C and its negative regulator MDM2, leading to the stabilization and activation of the tumor suppressor p53. This activation of p53 promotes cell cycle arrest and apoptosis, inhibiting the growth of XAGE-1C-expressing cancer cells.
Additionally, compounds such as WEE1 Inhibitor II and MEK Inhibitor indirectly inhibit XAGE-1C by targeting key signaling pathways involved in cell cycle regulation, such as the WEE1 kinase and the MAPK/ERK pathway, respectively. By blocking these pathways, these inhibitors disrupt the cellular processes necessary for XAGE-1C expression and tumor cell proliferation. Other inhibitors, such as Vorinostat and GSK-J4, target epigenetic regulators like histone deacetylases and histone demethylases, influencing chromatin structure and transcriptional regulation of XAGE-1C. Overall, the chemical class of XAGE-1C inhibitors provides valuable tools for studying the role of XAGE-1C in cancer biology and developing novel strategies for XAGE-1C-expressing malignancies.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3 inhibits XAGE-1C by disrupting its interaction with MDM2, leading to stabilization and activation of p53 tumor suppressor. | ||||||
AZ20 | 1233339-22-4 | sc-503186 | 5 mg | $255.00 | 1 | |
WEE1 Inhibitor II blocks the activity of WEE1 kinase, which indirectly inhibits XAGE-1C by regulating cell cycle progression. | ||||||
CAY10626 | 1202884-94-3 | sc-358741 sc-358741A | 1 mg 5 mg | $169.00 $756.00 | ||
PI3K Inhibitor CAY10626 blocks phosphoinositide 3-kinase (PI3K), potentially inhibiting downstream signaling pathways involved in XAGE-1C regulation. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat inhibits histone deacetylases (HDACs), which may modulate chromatin structure and affect XAGE-1C transcription. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the proteasome, leading to the degradation of proteins involved in cell cycle regulation, potentially including XAGE-1C. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
GSK-J4 inhibits histone demethylase JMJD3, which may affect chromatin remodeling and transcriptional regulation of XAGE-1C. | ||||||
MLN 8054 | 869363-13-3 | sc-484828 | 5 mg | $398.00 | ||
MLN8054 inhibits Aurora kinase A, a protein involved in cell cycle regulation, potentially impacting XAGE-1C expression. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib inhibits MEK1/2, components of the MAPK/ERK signaling pathway, which may indirectly affect XAGE-1C expression. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that may indirectly inhibit XAGE-1C by suppressing the MAPK/ERK signaling pathway. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which regulate cell cycle progression and may affect XAGE-1C expression. | ||||||